

CORRIGENDUM: Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal)

Kazuya Tsuboi MD and Hiroshi Yamamoto MD

Genet Med advance online publication, April 12, 2012; doi:10.1038/gim.2012.39

In the published version of this article, the authors neglected to acknowledge the expert support provided by some of their colleagues.

The authors wish to thank Prof Fumio Endo, Dr Kimitoshi Nakamura (School of Medicine, Kumamoto University) for completing enzyme activity measurements, and Prof Yoshikatsu Eto, Prof Toya Ohashi, and Dr Masahisa Kobayashi (The Jikei University School of Medicine) for performing gene mutation measurements. They would also like to acknowledge the contribution of all the patients who participated in this study, and Steve Clissold PhD, Content Ed Net, for editorial assistance, which was funded by Shire PLC, Japan.

The authors regret the oversight.